Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers develop Marburg virus treatment effective five days after infection

06.04.2017

Virus causes hemorrhagic fever often leading to death

An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical Inc., and Vanderbilt University. The findings are now available in Science Translational Medicine.


This is a micrograph of the Marburg virus.

Credit: The University of Texas Medical Branch at Galveston

There are currently no vaccines or drugs approved for human use to protect against the Marburg and Ravn viruses. These two filoviruses, which are in the same virus family as Ebola, cause severe and often lethal disease in people. The average case fatality rate of Marburg virus disease since the first recognized outbreak in 1967 is 80 percent.

Monoclonal antibodies are a technology that is currently in wide use for treating autoimmune diseases and cancers. There are more than 45 monoclonal antibodies approved by the U.S. Food and Drug Administration and European Medicines Agency.

"In this paper, we demonstrated that one monoclonal antibody is able to protect up to 100 percent of Marburg or Ravn virus-infected non-human primates when the antibody treatment is given up to five days following exposure to a lethal amount of the virus," said UTMB's Thomas Geisbert, professor in the department of microbiology and immunology. "These findings extend the growing body of evidence that monoclonal antibodies can provide protection during advanced stages of disease with highly dangerous viruses and could be useful during an epidemic."

The study was conducted in Biosafety Level (BSL)-4 at UTMB's Galveston National Laboratory. BSL-4 is a highly-restricted area where scientists wear positive pressure protective suits and study pathogens that cause severe and often fatal diseases. UTMB has the only functioning BSL-4 laboratory located on an American university campus.

The 2013 to 2016 Ebola virus epidemic highlighted the troubling lack of preventive or treatment options for filoviruses. Some of the therapeutics used to treat those infected with Ebola were developed and tested in the GNL.

"The level of protection observed by Dr. Geisbert's team with this antibody is very impressive. We plan to advance this product towards human safety testing as quickly as possible," said Larry Zeitlin, president of Mapp Biopharmaceutical Inc.

###

Other authors of this paper include UTMB's Chad Mire, Joan Geisbert, Viktoriya Borisevich, Karla Fenton, Krystle Agans and Daniel Deer; Andrew Flyak and James Crowe, Jr. from Vanderbilt University Medical Center; Herta Steinkellner from the University of Natural Resources and Life Sciences in Vienna and Ognian Bohorov, Natasha Bohorova, Charles Goodman, Andrew Hiatt, Do Kim, Michael Pauly, Jesus Velasco and Kevin Whaley.

This study was supported by the Department of Health and Human Services, National Institutes of Health and BSL-4 operations support of the Galveston National Laboratory.

Media Contact

Donna Ramirez
donna.ramirez@utmb.edu
409-772-8791

 @utmb_news

http://www.utmb.edu 

Donna Ramirez | EurekAlert!

Further reports about: Ebola diseases monoclonal antibodies primates viruses

More articles from Health and Medicine:

nachricht GLUT5 fluorescent probe fingerprints cancer cells
20.04.2018 | Michigan Technological University

nachricht Scientists re-create brain neurons to study obesity and personalize treatment
20.04.2018 | Cedars-Sinai Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

Im Focus: Basel researchers succeed in cultivating cartilage from stem cells

Stable joint cartilage can be produced from adult stem cells originating from bone marrow. This is made possible by inducing specific molecular processes occurring during embryonic cartilage formation, as researchers from the University and University Hospital of Basel report in the scientific journal PNAS.

Certain mesenchymal stem/stromal cells from the bone marrow of adults are considered extremely promising for skeletal tissue regeneration. These adult stem...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Structured light and nanomaterials open new ways to tailor light at the nanoscale

23.04.2018 | Physics and Astronomy

On the shape of the 'petal' for the dissipation curve

23.04.2018 | Physics and Astronomy

Clean and Efficient – Fraunhofer ISE Presents Hydrogen Technologies at the HANNOVER MESSE 2018

23.04.2018 | Trade Fair News

VideoLinks
Science & Research
Overview of more VideoLinks >>>